Forge Biologics has entered an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva platform.

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Ecolab Life Sciences has opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania.